Long-term Persistence of Hepatitis B Antibodies and Challenge Response in Adolescents

Phase 4, open-label, single-arm trial of hepatitis b vaccine recombinant in hepatitis B (HBV), sponsored by GSK. Primary endpoints: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Value at 1 month and Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ChemiLuminescence ImmunoAssay (CLIA) Equal to or Above Cut-off Value at 1 month. Started Oct 2009; status: completed.